On May 12th, the biaseparations.com website will be retired and migrated to sartorius.com. Learn more about our combined offering today!

Seminars & Webinars

2021

Event: Nucleic Acids- cGMP Production of mRNA & pDNA (virtual edition)

Date: February 1, 2021

Our new Head of Process Development for mRNA and pDNA purification, Rok Sekirnik, presented our Chromatographic tools for high-yielding mRNA production process as workshop.

Click here to listen to the workshop.


Event: Nucleic Acids- cGMP Production of mRNA & pDNA (virtual edition)

Date: February 3, 2021

Our CEO, Ales Strancar presented our Integrated Production Process of mRNA from E. coli to Highly Purified mRNA

Click here to listen to the presentation.

Attachments

Full view

2020

Presenter: Aleš Štrancar

Date: od demand, October 19-22, 2020

Cell & Gene Therapy Bioprocessing & Commercialization  (digital event)

Established processes for pDNA manufacturing include purification steps designed to enrich the supercoiled (sc) isoform. Homogeneous supercoiled isoform improves cell transfection efficiency in fermentation processes and is favoured in cell culture production systems. In vitro transcription (IVT), the enzymatic process used for production of mRNA vaccines differentiates itself from biological fermentation processes by the need for linearised plasmid DNA. The linear isoform is produced with restriction enzymes from open circular and supercoiled plasmid DNA. Employing a traditional pDNA manufacturing process, which removes linear and open-circular isoforms, will therefore reduce the production yield. When plasmid DNA and mRNA are treated as a single production process, the purification steps can be optimised, yields improved, and the overall production cost reduced.

A new purification approach starting from E.Coli all through to mRNA production is presented here. This new approach integrates a pDNA linearisation step before polishing of plasmid DNA. The polishing step, placed after enzymatic linearisation, purifies linear pDNA from enzyme and other unwanted process impurities. The linearised plasmid DNA is then used in IVT for production of mRNA. This approach further introduces mRNA purification tools for improved contaminant removal. The altered sequence of purification and linearisation reduces the overall number of purification steps required, improves recoveries, while the complete process results in extra low protein impurity and very efficient dsRNA removal.

Attachments

Full view

Messenger RNA is poised to become a major contributor in the fields of gene therapy and vaccines. Making this a practical reality requires purification technology that accommodates its unique features and challenges. Some of those challenges are inherent to mRNA. Others are byproducts of RNA synthesis.

This presentation addresses both and introduces a coordinated purification toolbox to advance the evolution of mRNA therapy.

Attachments

Full view

Presenter: Ingo Nagler

Date: June 3, 2020

Biomanufacturing and Cell & Gene Strategy Meetings (Proventa International's online meetings)

Click here to listen to BIA's Keynote Presentation

Attachments

Full view

Presenter: Ingo Nagler

Date: May 14, 2020

Asia’s SARS-CoV-2 Vaccine Development Challenges (Corona360 In-Conversation webcast series)

Attachments

Full view

Presenter: Pete Gagnon

Date: 23rd of January 2020

Place: Miami, FL (Phacilitate World Stem Cell Summit)

Attachments

Full view

2019

Presenter: Pete Gagnon

Date: September 18, 2019

Place: Boston, MA (Exosome Based Therapeutic Development Summit 2019)

Exosomes BIA Separations

Attachments

Full view

Presenter: Ales Strancar

Date: 19th of June 2019

Place: Biomanufacturing Training & Education Center (BTEC) in North Carolina

Attachments

Full view